Anzeige
Mehr »
Login
Mittwoch, 15.01.2025 Börsentäglich über 12.000 News von 681 internationalen Medien
Das 13-Millionen-Unternehmen mit einer Monster-Entdeckung!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QKNY | ISIN: SE0015195771 | Ticker-Symbol: 83A
Frankfurt
14.01.25
15:29 Uhr
3,500 Euro
0,000
0,00 %
Branche
Bau/Infrastruktur
Aktienmarkt
Sonstige
1-Jahres-Chart
FASADGRUPPEN GROUP AB Chart 1 Jahr
5-Tage-Chart
FASADGRUPPEN GROUP AB 5-Tage-Chart
GlobeNewswire (Europe)
171 Leser
Artikel bewerten:
(1)

Fasadgruppen Group AB: Interim report January-June 2024

Finanznachrichten News

Second quarter highlights

  • Net sales amounted to SEK 1,303.7 million (1,309.6) corresponding to -0.5 percent. The organic change was -4.2 percent in local currencies.
  • EBITA amounted to SEK 80.7 million (104.0) and the EBITA margin was 6.2 percent (7.9).
  • Adjusted EBITA amounted to SEK 81.2 million (127.5) and the adjusted EBITA margin was 6.2 percent (9.7).
  • Profit for the period amounted to SEK 31.4 million (56.3), earnings per share before and after dilution were SEK 0.65 (1.13).
  • Operating cash flow totalled SEK 92.2 million (116.1).
  • The order backlog amounted to SEK 3,001.4 million (3,527.9).

First half highlights

  • Net sales amounted to SEK 2,348.9 million (2,453.0), corresponding to -4.2 percent. The organic change was -7.6 percent in local currencies.
  • EBITA amounted to SEK 98.9 million (175.9) and the EBITA margin was 4.2 percent (7.2).
  • Adjusted EBITA amounted to SEK 101.5 million (201.7) and the adjusted EBITA margin was 4.3 percent (8.2).
  • Profit for the period amounted to SEK 21.5 million (85.1), earnings per share before and after dilution were SEK 0.45 (1.72).
  • Operating cash flow totalled SEK 110.7 million (193.1).

Significant events during the quarter

  • Fasadgruppen has launched a new subsidiary with a focus on solar cell solutions under the name Elenta Solar AB.

Events after the end of the period

  • Fasadgruppen has acquired Brenden, one of Norway's leading scaffolding companies.
  • Fasadgruppen has acquired steel and forging company JE:s Svets & Smide.

Condensed CEO comment from Martin Jacobsson: "Navigating tough market conditions"
"The tough competitive situation that has dominated the Swedish market in particular over the past year was still evident during the second quarter of the year. Demand for renovation services remained stable, but the number of competing tenders for every single project is well above what we normally see, which brings price pressure. This is also affecting ongoing projects, where the margin for additional work has decreased. We expect the situation to improve as the new construction market recovers and with several interest rate cuts expected ahead.

Sales in the second quarter amounted to SEK 1,303 million, a decrease of 0.5 percent in total and of 4.2 percent organically. The negative organic development comes from the Swedish operations and in particular those subsidiaries within new construction. Norway, Denmark and Finland exhibited positive organic growth in the quarter.

Adjusted EBITA totalled SEK 81.2 million, with a margin of 6.2 percent. The decline is mainly attributable to our Swedish operations. Price pressure from a continued challenging competitive situation and a weak new construction market were contributing factors to this outcome. Compared with the second quarter last year, earnings in Norway fell slightly, while Denmark and Finland developed positively.

All our businesses are working actively to protect their profitability in the current market. In Sweden, where the situation is toughest, some of the companies are indicating a slight improvement. Centrally, we have also taken a number of structural measures in the past quarter, including CEO changes and closer cooperation between certain companies to ensure that we have the right conditions to reverse the negative trend. We are also working to further clarify Fasadgruppen's values to customers in the form of security, delivery quality and the capacity to carry out several different measures on the building envelope within the same project."

Report presentation
The interim report will be presented in a conference call and webcast today on 15 August 2024 at 8.15 a.m. CEST.
Link to webcast: https://ir.financialhearings.com/fasadgruppen-group-q2-report-2024
Registration for participation by phone: https://conference.financialhearings.com/teleconference/?id=50048882

For more information, please contact:

Adrian Westman, Head of Communications & Sustainability
Mail: adrian.westman@fasadgruppen.se
Tel. +46 (0) 73-509 04 00

About Fasadgruppen

Fasadgruppen Group AB (publ) acquires and develops entrepreneurial specialist companies that care for and create sustainable properties. The Group's subsidiaries possess expertise in all aspects of exterior work on properties, such as façades, windows, balconies and roofs. Common to most services is that they contribute to greater energy efficiency and a better living environment. Fasadgruppen is listed on Nasdaq Stockholm (ticker: FG). For more information, visit www.fasadgruppen.se.

This information is information that Fasadgruppen is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-08-15 07:30 CEST.

© 2024 GlobeNewswire (Europe)
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.